LymeNet Home LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Menu

LymeNet on Facebook

LymeNet on Twitter




The Lyme Disease Network receives a commission from Amazon.com for each purchase originating from this site.

When purchasing from Amazon.com, please
click here first.

Thank you.

LymeNet Flash Discussion
Dedicated to the Bachmann Family

LymeNet needs your help:
LymeNet 2020 fund drive


The Lyme Disease Network is a non-profit organization funded by individual donations.

LymeNet Flash Post New Topic  New Poll  Post A Reply
my profile | directory login | register | search | faq | forum home

  next oldest topic   next newest topic
» LymeNet Flash » Questions and Discussion » Medical Questions » IVIG research at UNH

 - UBBFriend: Email this page to someone!    
Author Topic: IVIG research at UNH
northstar
Frequent Contributor (1K+ posts)
Member # 7911

Icon 1 posted      Profile for northstar     Send New Private Message       Edit/Delete Post   Reply With Quote 
Note: this is not to open up a flame war on
auto-immune vs. infection. This is meant to
share with those using IVIG, or for those considering it.



UNH Glycomics Center Helps Identify Sugar Linkage That Could Lead To Better Treatment For Autoimmune Diseases


May 12, 2008

Reporters and editors: UNH Glycomics Center director Vern Reinhold can be reached at 603-862-2527 or [email protected].

DURHAM, N.H. - Researchers at the University of New Hampshire Glycomics Center have helped identify a specific carbohydrate structure that confers anti-inflammatory activity to a glycoprotein antibody that could lead to improved treatment of autoimmune diseases like lupus or rheumatoid arthritis.

The study, reported in a recent edition of the journal Science, was led by immunologist Jeffrey Ravetch of Rockefeller University.

The work revolves around immunoglobulin G (IgG), the most abundant antibody in blood plasma. Intravenous immunoglobulin (IVIG) has within it a trace amount of a very active material that is effective in relieving the inflammatory affects of lupus, rheumatoid arthritis, asthma, and other autoimmune disorders.

But because of the trace amounts of active material, effective doses of IVIG need to be very high, frequently leading to unwanted side effects.

This study involved rebuilding the human IVIG into a fully active molecule with a slight modification to a carbohydrate residue.

These carbohydrate structures are linked to the immunoglobulin and referred to as glycans, and on the tip of this glycan is a specifically linked sialic acid.

All the sialic acid on IVIG was converted to the active linkage that confers anti-inflammatory properties.

Understanding and analyzing the exact structure of sialic acid was the contribution of the UNH Glycomics Center, headed by director and research professor Vernon Reinhold.

The center has developed tools and protocols using multidimensional mass spectrometry to determine the structure and functional relationships of these carbohydrates.

Reinhold notes that while most biopolymers are linear and thus relatively easy to sequence, bush-shaped carbohydrates have proved challenging.

"With sequential mass spectrometry, we systematically untangle this bush," says Reinhold. "We take it down to the trunk then try to put it back together to determine its structure."

Reinhold and Glycomics Center research scientist David Ashline helped Ravetch pinpoint exactly how sialic acid was linked, which let the researchers engineer a synthetic human antibody that mimicked the linkages in IgG, providing an IVIG with enhanced activity for treatment of autoimmune diseases.

In the Science paper, the researchers report that when given to arthritic mice, the engineered IgG was about 30 times more effective than IVIG.

"Now that we know what the exact structure is, we can build on it," says Reinhold. "Just as once you know what the motor in a car is, you can modify and make it more effective, and in principle, if you know the antigen, you can build the antibody."

Beyond this work with IgG, the Glycomics Center is demystifying the carbohydrate connections in cancer that contributes to metastatic growth and in avian flu where sialic residues on airway surface tissues serve as doorways for viral entry.

"Carbohydrates are the glue that pulls things together, the cell surface matrix in which cells communicate, and they provide the connections for signal transduction.

It's only been within the last decade that we've realized that such structures are critical for all kinds of biological function," says Reinhold. "Now that we can define precise structures, we can begin to understand their function.

This structure-functional relationship will have a huge impact on our health in respect to immune regulation."

To read the abstract of the article, from the April 18 issue of Science, go to http://www.sciencemag.org/cgi/content/abstract/sci;320/5874/373.

Posts: 1331 | From hither and yonder | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code� is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | LymeNet home page | Privacy Statement

Powered by UBB.classic™ 6.7.3


The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:

The Lyme Disease Network of New Jersey
907 Pebble Creek Court, Pennington, NJ 08534 USA


| Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet | Contact Us

© 1993-2020 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to Terms and Conditions.